FDA Approved Tecentriq – How It Affected Our Price Estimate For Roche?

+29.53%
Upside
32.64
Market
42.28
Trefis
RHHBY: Roche logo
RHHBY
Roche

>> FDA Approved Roche’s Tecentriq (atezolizumab) which is used to treat bladder cancer

roche- tecentriq- price estimate

Have more questions about Roche? See the links below.

Relevant Articles
  1. Is Roche Stock Undervalued At $33?
  2. What’s Driving Roche Stock?
  3. Company Of The Day: Roche Holdings
  4. What’s Happening With Roche (RHHBY) Stock?
  5. What’s Next For Roche Stock?
  6. Should You Buy, Sell, Or Hold Roche Stock At $42?

Notes:

1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our complete analysis for Roche

See More at Trefis | View Interactive Institutional Research (Powered by Trefis)

Get Trefis Technology

A Message From Trefis Marketing

Download our eBook “Create More Accurate Forecasts and Plans” and learn:

  • The costs of missed forecasts
  • The three reasons why companies do a poor job
  • How you can create more accurate forecasts and plans

Click here